Comparison
PT-141 vs Kisspeptin
Brain-signaling versus hormone-signaling approaches
The key difference
PT-141 (bremelanotide) acts on melanocortin receptors in the brain involved in desire. Kisspeptin sits at the top of the reproductive hormone chain, triggering GnRH release.
| PT-141 | Kisspeptin | |
|---|---|---|
| Class | Melanocortin receptor agonist | Reproductive hormone peptide |
| Evidence | FDA-approved drug | Early human research |
| Status | Prescription drug. FDA-approved for one specific indication. | Not FDA-approved. |
| Also known as | Bremelanotide, Vyleesi | — |
| Researched for | Sexual wellness | Sexual wellness |
| Evidence strength | FDA-approved drug | Early human research |
What else differs
- PT-141 is FDA-approved for one specific indication in premenopausal women.
- Kisspeptin is primarily a research tool in reproductive endocrinology.
Bottom line
Different systems entirely; only one has an approval.
Read the research
PT-141 on PubMed →
Kisspeptin on PubMed →
Educational content, not medical advice. This page does not recommend or dose any substance. Compounds that are not FDA-approved have not been established as safe or effective in people.